Abstract

Owing to retained hepatic phenotypes and functions, human three-dimensional (3D) hepatic models established with diverse hepatic cell types are thought to recoup the gaps in drug development and disease modeling limited by a conventional two-dimensional (2D) cell culture system and species-specific variability in drug metabolizing enzymes and transporters. Primary human hepatocytes, human hepatic cancer cell lines, and human stem cell–derived hepatocyte-like cells are three main hepatic cell types used in current models and exhibit divergent hepatic phenotypes. Primary human hepatocytes derived from healthy hepatic parenchyma resemble in vivo–like genetic and metabolic profiling. Human hepatic cancer cell lines are unlimitedly reproducible and tumorigenic. Stem cell–derived hepatocyte-like cells derived from patients are promising to retain the donor’s genetic background. It has been suggested in some studies that unique properties of cell types endue them with benefits in different research fields of in vitro 3D modeling paradigm. For instance, the primary human hepatocyte was thought to be the gold standard for hepatotoxicity study, and stem cell–derived hepatocyte-like cells have taken a main role in personalized medicine and regenerative medicine. However, the comprehensive review focuses on the hepatic cell type variety, and corresponding applications in 3D models are sparse. Therefore, this review summarizes the characteristics of different cell types and discusses opportunities of different cell types in drug development, liver disease modeling, and liver transplantation.

Highlights

  • The liver is one of the largest organs in the body and plays a critical role in drug metabolism

  • Emerging in vitro human hepatic 3D models maintaining hepatic phenotypes and functions increase the predictability of drug-induced liver injury (DILI), allow for faithful metabolite profiling and disease imitating, and benefit exploration of idiosyncratic drug effects as well

  • primary human hepatocyte (PHH), HepaRG, HepG2, hiPSC/hESC-hepatocyte-like cells (HLCs), and human adult stem cells (hASCs)-HLCs were mostly involved in the above applications

Read more

Summary

Introduction

The liver is one of the largest organs in the body and plays a critical role in drug metabolism. Hepatic disease accounts for approximately 2 million deaths per year worldwide, of which 1 million are due to complications of cirrhosis and 1 million are due to viral hepatitis and hepatocellular carcinoma (Asrani et al, 2019). Establishing a suitable modeling paradigm is essential for preclinical drug development and disease study. Species-specific drug metabolizing enzymes and transporters (DMETs) involved in drug absorption, distribution, metabolism, and excretion alter the drug metabolic pathway, hampering the application of animal models in human toxicity prediction (Olson et al, 2000; Cheung and Gonzalez, 2008). Conventional 2D monolayer culture has been proved with uniform exposure to signaling cues and nutrients and less cell–cell and cell–matrix interactions.

Objectives
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call